Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2011-05-17
2011-05-17
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C424S401000
Reexamination Certificate
active
07943604
ABSTRACT:
The invention relates to cosmetic methods of treating human skin. The method includes applying to the skin a composition containing an estrogenic component and a cosmetically acceptable vehicle. Other aspects of the invention relate to therapeutic methods of treating or preventing vaginal dryness or acne and a therapeutic method of promoting wound healing. Another aspect relates to a skin care composition comprising the aforementioned estrogenic component and a cosmetically acceptable vehicle.
REFERENCES:
patent: 3440320 (1969-04-01), Sackler et al.
patent: 3797494 (1974-03-01), Zaffaroni
patent: 4460372 (1984-07-01), Campbell et al.
patent: 4573996 (1986-03-01), Kwiatek et al.
patent: 4624665 (1986-11-01), Nuwayser
patent: 4722941 (1988-02-01), Eckert et al.
patent: 4762717 (1988-08-01), Crowley, Jr.
patent: 4937238 (1990-06-01), Lemon
patent: 5130137 (1992-07-01), Crowley, Jr.
patent: 5211952 (1993-05-01), Spicer et al.
patent: 5223261 (1993-06-01), Nelson et al.
patent: 5340584 (1994-08-01), Spicer et al.
patent: 5340585 (1994-08-01), Pike et al.
patent: 5340586 (1994-08-01), Pike et al.
patent: 5468736 (1995-11-01), Hodgen
patent: 5633242 (1997-05-01), Oettel et al.
patent: 5662927 (1997-09-01), Ehrlich et al.
patent: 5827843 (1998-10-01), Koninckx
patent: 6214815 (2001-04-01), Shangold et al.
patent: 6500814 (2002-12-01), Hesch
patent: 2002/0183299 (2002-12-01), Voskuhl
patent: 2004/0192598 (2004-09-01), Kragie
patent: 2336433 (1975-04-01), None
patent: 2336434 (1975-04-01), None
patent: 2426779 (1975-12-01), None
patent: 19917930 (2000-10-01), None
patent: 0402950 (1975-12-01), None
patent: 468690 (1991-07-01), None
patent: 1700602 (2001-05-01), None
patent: 9218107 (1992-10-01), None
patent: 9426207 (1994-11-01), None
patent: 9502408 (1995-01-01), None
patent: 9517895 (1995-07-01), None
patent: 9603929 (1996-02-01), None
patent: 9858657 (1998-12-01), None
patent: 0073416 (2000-12-01), None
patent: 0130357 (2001-05-01), None
patent: 0185154 (2001-11-01), None
patent: WO 03/018026 (2003-03-01), None
Webster Ninth New Collegiate Dicitionary, 2000, Definition of Prevention, p. 1.
Willhite et al. Pharmacotherapy, 2001, vol. 21, Issue 4, pp. 464-480.
Sitruk-Ware, English Translation, 1997. Praxis, Schweirzerische Rundschau fur Medizin, vol. 86, No. 33, pp. 1-13.
Younglai et al. Journal of Clinical Endocrinology and Metabolism, 1968, vol. 28, Issue 11, pp. 1611-1617.
Holinka et al. In vivo Effects of Estetrol on the Immature Rat Uterus. Biology of Reproduction 1979, vol. 20, pp. 242-246.
Mueck et al., “Angio and Anti-Angiogenetic Effects of Estradiol and its Metabolites”, J. Clin. Basic Cardiol., 2001, pp. 153-155, vol. 4, No. 2.
Shah et al., “Estrogen and Skin. An Overview”, Am. J. Clin. Dermatol., 2001, pp. 143-150, vol. 2, No. 3.
Sitruk-Ware et al., “Local Hormonal Treatment for Urogenital Atrophy After Menopause”, Shweiz. Rundsch, Med. Praxis, 1997, pp. 1245-1248, vol. 86, No. 33.
Schmidt et al., “Treatment of Skin Aging with Topical Estrogens”, Int. J. Dermatol., 1996, pp. 669-674, vol. 35, No. 9.
National Institute of Child Health and Human Development, NIH Publication No. 02-2413 retrieved online on Aug. 9, 2007.
Breast Cancer Prevention retrieved online Aug. 7, 2007 from the internet; http://www.cancer.gov/cancertopics/pdq/prevention/breast/Patient/page 3.
Prophylactic definition—Medical Dictionary of Popular Medical Terms; retrieved on Mar. 14, 2008 via www.medterms.com/script/main/art.asp?articlekey+11902.
Zips et al., in vivo, 2005, vol. 19, pp. 1-8.
Holinka et al., Biology of Reproduction, 1980, vol. 22, pp. 913-926.
Martucci et al., “Impact of Continuously Administered Catechol Estrogens on Uterine Growth and Luteinizing Hormone Secretion”, Endocrinology (Dec. 1979), vol. 105, No. 6, pp. 1288-1292.
Weigert et al., “Comparison of Stimulation with Clomiphenes Citrate in Combination with Recombinant Follicle Stimulating Hormone and Recombinant Luteinizing Hormone to Stimulation with a Gonadotropin-Releasing Hormone Agonist Protocol: A Prospective Randomized Study”, Fertility and Sterility, (Jul. 2002), vol. 78, No. 1, pp. 34-39.
Trotter et al., “Effects of Postnatal Estradiol and Progesterone Replacement in Extremely Preterm Infants”, J. Clin. Endocrinol Metab., (Dec. 1999), vol. 84, No. 12, pp. 4531-4535.
Shanklin et al., “Aqueous Estrogens in the Management of Respiratory Distress SYndrome”, J. Reprod. Med. (Aug. 1970), vol. 5, No. 2, pp. 53-71.
Chemical Abstracts Service, Columbus Ohio, US: Jakowicki, “Evaluation of Estriol Level in the Amniotic Fluid in Prolonged Pregnancy”, XP002458625, 1979.
Gorwill et al., “Unconjugated Serum Oestriol Levels in Mother and Baby with Meconium Staining of the Amniotic Fluid”, Br. J. Obstet. Gynaecol. (Aug. 1978), vol. 85, No. 8, pp. 602-604.
Fogary, Jr., “Postmaturity”, J. Am. Osteopath. Assoc., (Jan. 1976), vol. 75, No. 5, pp. 512-517.
Office Action mailed on Jan. 11, 2008 in U.S. Appl. No. 10/478,262.
Office Action mailed on May 15, 2008 in U.S. Appl. No. 10/478,262.
Office Action mailed on Feb. 19, 2009 in U.S. Appl. No. 10/478,262.
Office Action mailed on Jun. 9, 2009 in U.S. Appl. No. 10/478,262.
Office Action mailed on Nov. 18, 2008 in U.S. Appl. No. 10/478,264.
Office Action mailed on May 22, 2009 in U.S. Appl. No. 10/478,264.
Office Action mailed on Mar. 17, 2008 in U.S. Appl. No. 10/478,357.
Office Action mailed on May 16, 2008 in U.S. Appl. No. 10/478,357.
Office Action mailed on Dec. 16, 2008 in U.S. Appl. No. 10/478,357.
Office Action mailed on May 28, 2009 in U.S. Appl. No. 10/478,357.
Office Action mailed on Apr. 6, 2007 in U.S. Appl. No. 10/478,365.
Office Action mailed on Sep. 7, 2007 in U.S. Appl. No. 10/478,365.
Office Action mailed on Apr. 1, 2008 in U.S. Appl. No. 10/478,365.
Office Action mailed on Jun. 8, 2009 in U.S. Appl. No. 10/478,365.
Office Action mailed on Jan. 24, 2007 in U.S. Appl. No. 10/495,707.
Office Action mailed on Dec. 28, 2007 in U.S. Appl. No. 10/495,707.
Office Action mailed on Aug. 19, 2008 in U.S. Appl. No. 10/495,707.
Office Action mailed on May 22, 2009 in U.S. Appl. No. 10/495,707.
Office Action mailed on Aug. 9, 2007 in U.S. Appl. No. 10/517,686.
Office Action mailed on Apr. 4, 2008 in U.S. Appl. No. 10/517,686.
Office Action mailed on May 29, 2009 in U.S. Appl. No. 10/517,686.
Office Action mailed on Apr. 23, 2007 in U.S. Appl. No. 10/521,040.
Office Action mailed on Aug. 17, 2007 in U.S. Appl. No. 10/521,040.
Office Action mailed on Apr. 2, 2008 in U.S. Appl. No. 10/521,040.
Office Action mailed on Jun. 1, 2009 in U.S. Appl. No. 10/521,040.
Visser et al., “In vitro effects of estetrol on receptor binding, drug targets and human liver cell metabolism,” Climacteric (2008) 11(1) Appx. II: 1-5.
Visser et al., “First human exposure to exogenous single-dose oral estetrol in early postmenopausal women,” Climacteric (2008) 11(1): 1-10.
Visser et al., “Clinical applications of estetrol,” J. of Steroid Biochem and Molecular Biol. (2009) 114: 85-89.
Holinka et al., “Estetrol: A unique steroid in human pregnancy,” J. of Steroid Biochem and Molecular Biol. (2009) 110: 138-143.
Coelingh Bennink et al., “Oral bioavailability and bone sparing effects of estetrol in an osteoporosis model,” Climacteric (2008) 11 (Supp 3): 1-13.
Albertazzi Paola et al., “The Effect of Tibolone Versus Continuous Combined Norethisterone Acetate and Oestradiol on Memory, Libido and Mood of Postmenopausal Women: A Pilot study”; Database Biosis ′Onlinel; Oct. 31, 2000; pp. 223-229; vol. 36, No. 3; Biosciences Information Service, Philadelphia, PA., U.S.
Allen et al., An Ovarian Hormone: Preliminary Report on Its Localization, Extraction and Partial Purification, and Action in Test Animals, JAMA, Sep. 8, 1923, vol. 81, pp. 819-821.
Allen et al., The Induction of a Sexually Mature Condition in Immature Females by Injection of the Ovarian Follicular Hormone, Am. J. Physiol.,
Bennink Herman Jan Tijmen Coelingh
Bunschoten Evert Johannes
Holinka Christian Franz
Jean-Louis Samira
Padmanabhan Sreeni
Pantarhei Bioscience B.V.
The Webb Law Firm
LandOfFree
Method of treating human skin and a skin care composition... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating human skin and a skin care composition..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating human skin and a skin care composition... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2670148